Sekretessinställningar
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Aktiemarknader
    • BörsRealtidskurser, index och marknadsutveckling
    • MorgonrapportDaglig marknadssammanfattning och nattens viktigaste händelser
    • BörskalenderKommande resultat, noteringar och företagshändelser
    • UtdelningskalenderKommande och tidigare utdelningar
  • Bolag
    • BolagBläddra och filtrera hela listan över noterade bolag
    • UpptäckInspiration till din nästa investering
    • BörsnoteringarNya noteringar och kommande börsintroduktioner
    • ÅrsstämmorDatum för årsstämmor och aktieägarinformation
  • Aktieforskning
    • AktieanalysExpertaktieanalys och rekommendationer
    • ArtiklarNyheter, insikter och marknadskommentarer
    • PortföljInderes modellportfölj
  • Lär dig om investeringar
    • AnalysskolaLär dig läsa och förstå aktieanalys
    • inderesTVVideohub för aktieanalys, forskning och expertkommentarer
    • TranskriptionerFullständiga utskrifter av resultatsamtal och investerarmöten
    • AktiejämförelseJämför nyckeltal och utveckling för flera aktier
    • Earnings SeasonCompare EPS estimates to reported results
    • InsideraffärerFölj köp- och säljaktivitet hos företagsinsiders
    • BlankningSe vilka börsnoterade bolag som har offentliggjorda korta positioner
    • Virtuell analytikerchattStäll frågor och få AI-drivna investeringsinsikter direkt
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Följ oss på våra kanaler i social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Ta kontakt
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • Om oss
  • Teamet
  • Jobba hos oss
  • Inderes som en investering
  • Tjänster för börsbolag
Vår plattform
  • FAQ
  • Q&A
  • Servicevillkor
  • Integritetspolicy
  • Disclaimer

Inderes disclaimer gällande utförda aktieanalyser kan läsas här. För mer detaljerad information över de aktier som aktivt bevakas av Inderes, vänligen se respektive bolags bolagsspecifika sida på Inderes webbplats. © Inderes Oyj. Alla rättigheter förbehållna.

Saniona AB’s Nomination Committee for the Annual General Meeting 2027

SANIONPressmeddelande2026-11-03 08:00

Saniona (OMX: SANION), a clinical stage biopharmaceutical company, today announces the composition of the Nomination Committee for the Annual General Meeting 2027

Pursuant to the instruction and charter for the Nomination Committee adopted by the general meeting, the Nomination Committee shall comprise three members, which shall be the Chairman of the Board of Directors and two members appointed by the two largest shareholders as of last September. On September 30, 2026, the two largest shareholders, who desired to appoint representatives to the Nomination Committee, were Handelsbanken Fonder AB and Joakim Tedroff. Each such shareholder has appointed a representative, as shown below, who together with the Chairman of the Board of Directors will form Saniona AB’s Nomination Committee for the Annual General Meeting 2027.

The Nomination Committee’s members are:
• Anna Sundberg, appointed by Handelsbanken Fonder AB
• Joakim Tedroff, CMO at Irlab Therapeutics AB, appointed by Joakim Tedroff
• John Haurum, Chairman of Saniona AB’s Board

Anna Sundberg has been appointed as Chairman of the Nomination Committee.

The Nomination Committee shall prepare and submit proposals to the Annual General Meeting 2027 regarding:
• election of the Chairman at the Annual General Meeting;
• election of the Chairman and other members of the Board;
• remuneration for the Chairman and for each of the other members of the Board and, if applicable, remuneration for committee work;
• election of the auditor and the auditor’s remuneration; and
• principles for appointing the Nomination Committee.

The instruction and charter for the Nomination Committee can be found in the Corporate Governance section at the company’s website, www.saniona.com.

Saniona AB’s Annual General Meeting will be held on Monday May 24, 2027, in Malmö. The Nomination Committee’s proposals will be presented in the notice to the Annual General Meeting and on the company’s website.

Shareholders who would like to submit proposals to the Nomination Committee can do so via e-mail to clo@saniona.com marked “Recommendation to the Nomination Committee” or by ordinary mail to the address:

Saniona AB
Att: Recommendation to the Nomination Committee
Murervangen 42
DK-2600 Glostrup
Denmark

To ensure that the proposals can be considered by the Nomination Committee, proposals shall be submitted in due time before the Annual General Meeting, but not later than February 28, 2027.

About Saniona
Saniona is a clinical-stage biopharmaceutical company focused on discovering, developing, and delivering innovative treatments for neurological and psychiatric disorders. The company’s internal pipeline includes SAN2668 for pediatric epilepsy syndromes and SAN2465 for major depressive disorder. Saniona has established strategic collaborations with leading pharmaceutical companies, including Jazz Pharmaceuticals, which holds global rights to SAN2355 for epilepsy, Acadia Pharmaceuticals, which holds worldwide rights to ACP-711 for essential tremor, and with Medix, which holds rights to tesofensine for obesity in Mexico, and Argentina. Saniona’s ion channel discovery platform is further validated through research collaborations with Boehringer Ingelheim, Cephagenix and AstronauTx, which holds worldwide rights to ATX0926. Headquartered in Copenhagen, Saniona is listed on the Nasdaq Stockholm Main Market.
For more information, visit www.saniona.com.

For more information, please contact
Johnny Stilou, CFO, +45 21227227; johnny.stilou@saniona.com

Attachments
Saniona AB’s Nomination Committee for the Annual General Meeting 2027